Brokerages forecast that Chimerix Inc (NASDAQ:CMRX) will announce earnings of ($0.37) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Chimerix’s earnings. The highest EPS estimate is ($0.34) and the lowest is ($0.42). Chimerix reported earnings per share of ($0.57) during the same quarter last year, which would suggest a positive year-over-year growth rate of 35.1%. The company is expected to issue its next quarterly earnings report before the market opens on Tuesday, May 9th.
According to Zacks, analysts expect that Chimerix will report full-year earnings of ($1.68) per share for the current year, with EPS estimates ranging from ($1.94) to ($1.50). For the next year, analysts anticipate that the business will report earnings of ($1.71) per share, with EPS estimates ranging from ($2.41) to ($0.89). Zacks’ earnings per share averages are an average based on a survey of research analysts that cover Chimerix.
Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Thursday, March 2nd. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.05. Chimerix had a negative net margin of 1,451.99% and a negative return on equity of 32.09%. The business had revenue of $1.98 million for the quarter, compared to analyst estimates of $0.89 million.
A number of analysts have recently weighed in on CMRX shares. Zacks Investment Research upgraded shares of Chimerix from a “hold” rating to a “buy” rating and set a $5.75 price target on the stock in a report on Tuesday, January 10th. FBR & Co restated a “hold” rating and issued a $7.00 price target on shares of Chimerix in a report on Monday, May 1st. Finally, Cowen and Company restated a “hold” rating and issued a $6.00 price target on shares of Chimerix in a report on Friday, April 28th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Chimerix has an average rating of “Hold” and an average target price of $7.55.
Chimerix (NASDAQ:CMRX) traded up 0.19% during midday trading on Monday, reaching $5.17. 266,461 shares of the company traded hands. Chimerix has a one year low of $3.50 and a one year high of $6.64. The stock’s market capitalization is $240.69 million. The company has a 50 day moving average price of $5.95 and a 200-day moving average price of $5.31.
Several hedge funds have recently added to or reduced their stakes in the stock. Teza Capital Management LLC purchased a new stake in Chimerix during the first quarter worth $135,000. Nationwide Fund Advisors boosted its stake in Chimerix by 5.9% in the first quarter. Nationwide Fund Advisors now owns 35,573 shares of the biopharmaceutical company’s stock worth $227,000 after buying an additional 1,977 shares in the last quarter. Tudor Investment Corp Et Al boosted its stake in Chimerix by 74.9% in the fourth quarter. Tudor Investment Corp Et Al now owns 50,950 shares of the biopharmaceutical company’s stock worth $234,000 after buying an additional 21,823 shares in the last quarter. Bank of Montreal Can boosted its stake in Chimerix by 3.8% in the first quarter. Bank of Montreal Can now owns 39,300 shares of the biopharmaceutical company’s stock worth $251,000 after buying an additional 1,448 shares in the last quarter. Finally, Teachers Advisors LLC boosted its stake in Chimerix by 0.3% in the fourth quarter. Teachers Advisors LLC now owns 69,888 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 204 shares in the last quarter. Institutional investors and hedge funds own 68.66% of the company’s stock.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Get a free copy of the Zacks research report on Chimerix (CMRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com